¹**Sex-specific Risk Factors for Survival in B-cell Non-Hodgkin Lymphoma Patients after Anti-CD19** ²**CAR T-Cell Therapy** 3 4 Manishkumar S. Patel¹, Agrima Mian², Akansha Jalota¹, Peter Bazeley³, Sujata Patil^{3,4}, Brian T. Hill², and 5 Neetu Gupta 1 6 ¹Department of Inflammation and Immunity, Lerner Research Institute; ²Department of Hematology and 8 Medical Oncology, Taussig Cancer Institute; ³Department of Quantitative Health Sciences, Lerner 9 Research Institute; ⁴Department of Cancer Biostatistics, Taussig Cancer Institute, Cleveland Clinic, 10 Cleveland, OH 11 ¹²**Correspondence to:** Neetu Gupta, Ph.D.; 9500 Euclid Avenue, NE40, Cleveland, OH 44195; Email: 13 guptan@ccf.org; Phone: (216) 444-7455; Fax: (216) 444-9329 14 ¹⁵**Running Title:** Sex-specific risk factors in CAR T-cell therapy ¹⁶**Keywords:** CAR T-cells, lymphoma, survival, biological sex 17

¹⁹**Abstract**

²⁰Sex bias is well documented in autoimmune diseases, cancer and immune responses to infectious agents. 21 Here, we investigated if pre-treatment risk factors that influence the survival of B-cell non-Hodgkin 22 lymphoma (NHL) patients after anti-CD19 CAR T-cell therapy are sexually dimorphic. We measured 23 pre-leukapheresis tumor burden (lactate dehydrogenase levels), C-reactive protein (CRP) and serum 24 cytokine and chemokine concentration in 67 B-cell NHL patients treated with axicabtagene ciloleucel 25 (axi-cel) or tisagenlecleucel (tisa-cel). Association of relative abundance of each factor with progression-26 free survival (PFS) and overall survival (OS) was analyzed in male and female patients together, or only 27 within the male cohort or only within the female cohort. No differences in PFS or OS or in pre-treatment 28 tumor burden, CRP and cytokine/chemokine levels were observed between male and female patients 29 undergoing axi-cel or tisa-cel therapy. However, within the male group, patients with higher pre-treatment 30 tumor burden and greater relative abundance of CRP and pro-inflammatory cytokines and chemokines 31 conferred greater risk of poor progression-free survival (PFS) and/or overall survival (OS). In contrast, 32 within the female group, patient survival was largely agnostic to variations in tumor burden, CRP and 33 cytokine/chemokine abundance. Specifically, higher relative abundance of IL-6, IL-8, IL-27, TNF- α , ³⁴Eotaxin-1, MIP-1β and MCP-1 was associated with poor PFS and/or OS after CAR T-cell therapy within 35 the male group, whereas higher IL-27 and IFN α 2 abundance was associated with better PFS and poorer ³⁶OS, respectively, within the female group. Our data suggest that biological sex may modulate the impact 37 of baseline risk factors on survival outcomes of CAR T-cell therapy in B-cell NHL.

³⁹**Introduction**

⁴⁰Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy demonstrates remarkable efficacy for the 41 treatment of refractory/relapsed (r/r) large B-cell lymphoma (LBCL), follicular lymphoma and mantle cell 42 lymphoma¹⁻³. However, ~40-60% of patients treated with CAR-T cell therapy exhibit poor response and 43 survival¹⁻⁴. This has spurred the need to identify pre-treatment biomarkers of response to anti-CD19 CAR ⁴⁴T-cell therapy. In addition to tumor characteristics and intrinsic composition/attributes of CAR-T cells, 45 the inter-patient heterogeneity in immunological signatures may influence response to this therapy. ⁴⁶Further, factors that do not directly stem from the immune system, such as sex, race and ethnicity may 47 play a role in modulating and/or predicting the survival of patients undergoing CAR T-cell therapy. ⁴⁸Indeed, race and ethnicity were recently shown to contribute to the differences in response to CAR T-cell t_1 49. therapy⁵. However, as race and ethnicity are more complex to define, self-reported race is widely 50 recognized as an incomplete interpretation of genetic ancestry or human genetic variation⁶. Further, as 51 reporting these variables is not mandatory⁷ and complete medical records for race and ethnicity are not 52 available for all patients seen at Cleveland Clinic, the present study is unable to address the impact of race 53 and ethnicity on outcomes.

54

⁵⁵On the other hand, it is well-established that the male and female immune systems are different, and that 56 immune responses to infections⁸, many autoimmune diseases⁹⁻¹¹, and tumor pathology^{12,13} exhibit sex 57 bias. Sex differences can alter the tumor microenvironment¹⁴ and modulate immune system homeostasis 58 and responses via inflammatory cytokine production¹⁵, ¹⁶. The impact of sex has also been reported in the 59 efficacy¹⁷ and survival outcomes of patients¹⁸ receiving immune checkpoint inhibitors for solid tumors. ⁶⁰Therefore, baseline tumor burden and cytokine/chemokine profiles in male and female patients may 61 differentially impact the survival outcomes of anti-CD19 CAR T-cell therapy. Understanding these 62 differences may provide insights into sex-specific biomarkers of survival and enable better stratification

⁶³of outcomes. As biological sex at birth is reported for all patients undergoing anti-CD19 CAR T-cell 64 therapy, we focused on investigating potential differences in outcomes based on baseline features of 65 responding and non-responding male and female cohorts.

66

⁶⁷We examined if baseline cytokine/chemokine levels and tumor burden affect the survival of LBCL ⁶⁸patients treated with *axicabtagene ciloleucel* (axi-cel) or *tisagenlecleucel* (tisa-cel) in a sex-specific 69 manner. We demonstrate that male B-NHL patients with elevated baseline abundance of IL-8, IL-6, IL-⁷⁰27, Eotaxin-1, MIP-1β, MCP-1, TNF-α and CRP, as well as higher pre-treatment tumor burden exhibit 71 poorer survival compared to those with lower abundance of these factors. On the other hand, within the 72 female patient cohort, the survival outcomes are largely unaffected by the relative abundance of these 73 factors. Our data suggest that an unfavorable baseline circulating cytokine/chemokine profile and high ⁷⁴pre-treatment tumor burden may collaborate to lower the survival of male patients undergoing anti-CD19 75 CAR T-cell therapy.

⁷⁷**Materials and Methods**

⁷⁸**Patient enrollment, specimen collection protocol, and clinical data**

79 All patients with r/r B-cell NHL (n=67) who received treatment with axi-cel (n=45) or tisa-cel (n=22) 80 between 2018 and 2021 and gave informed consent for blood sample collection were included in this ⁸¹IRB-approved study, which was executed in accordance with the declaration of Helsinki. In addition to 82 routine blood collection for clinical care, peripheral blood was also collected on the day of leukapheresis ⁸³(baseline) and serum was stored for inclusion in the institutional biorepository. The patient cohort is 84 represented by 46 males and 21 females and represents the observed male/female ratio within the B-NHL 85 . population^{19,20}. Baseline clinical characteristics and demographic details were retrieved through an IRB-86 approved retrospective chart review of the electronic medical record system and maintained in a secure 87 and HIPPA-compliant Research Electronic Data Capture (REDCap) system. Clinical outcomes including 88 progression-free survival (PFS) and overall survival (OS) were recorded relative to the date of CAR T-89 cell infusion. Patients who did not experience the event by the end of the study period or lost to follow-up ⁹⁰were censored for these time-to-event outcomes. Circulating lactate dehydrogenase (LDH) and C-reactive 91 protein (CRP) levels were measured on the day of leukapheresis.

⁹³**Cytokine/Chemokine and tumor burden quantification**

Multiplexed bead arrays (Eve Technologies, Alberta, Canada) were used to quantify serum levels of 29 cytokines and chemokines, including IL-1RA, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-15, IL-18, IL-21, IL-27, IFNα2, IFN-γ, TNF-α, Eotaxin-1, MIP-1α, MIP-1β, MCP-1, Flt3L, Fractalkine, G-CSF, 97 GM-CSF, IP-10, MDC, RANTES, sCD40L and VEGF-A.

98

⁹⁹**Data processing and quality control**

¹⁰⁰Cytokine/chemokine levels were measured in three batches. Cytokines with >20% of missing values (Out 101 of range-OOR) across patients in each batch were removed. Cytokines with \leq 20% missing values were 102 imputed as follows²¹. OOR values were replaced with median values; OOR< (out of range at the lower 103 end) and OOR> (out of range at the higher end) were imputed with half of the minimum observed value ¹⁰⁴across all samples and double of the maximum value observed across all samples, respectively. The 105 concentrations were log-transformed and a PCA plot was generated (Supplemental Fig. 1A) to identify 106 batch effects, using the PCA function in the FactoMineR package. Batch correction was performed using ¹⁰⁷"scale and center" in R and the removal of batch effects was again confirmed by generating a PCA plot ¹⁰⁸(Supplemental Fig. 1B). Batch-corrected relative abundance of each cytokine/chemokine was used for the 109 analysis of association with survival outcomes.

110

¹¹¹**Assessment of clinical response**

¹¹²Response assessment was performed 3 months after CAR T-cell therapy using the Lugano classification 113 system and defined as a complete metabolic response, partial response, stable disease, or progressive 114 disease, based on FDG uptake on PET-CT²². Response groups were defined based on ORR = overall 115 response rate (includes complete response $[CR]$ and partial response (PR)), and $NR =$ no response 116 (includes progressive disease [PD], stable disease [SD], death).

117

¹¹⁸**Association and statistical analysis**

119 These analyses had two main goals: to evaluate differences in tumor burden (i.e. LDH), CRP,

120 and each cytokine/chemokine by sex and to evaluate the association of tumor burden, CRP, and

121 each cytokine/chemokine with OS and PFS by sex. Due to skewness, all cytokine, chemokine,

¹²²LDH and CRP values were log-transformed prior to analysis. These variables were also made

123 binary at established cutoffs or if no established cutoffs existed, at the sex-specific median.

- ¹²⁴Specifically, for LDH, the indication for tumor burden was calculated using two established
- 125 cutoffs: one at \geq 250 U/l²³ and the other at \geq 400 U/l²⁴. For all other cytokines and chemokines,
- 126 cutoffs at sex-specific medians were used. Differences in each continuous variable by sex was
- 127 assessed using a two-sample Wilcoxon test. For males and females separately, the association of
- 128 each binary variable with OS and PFS was assessed using the Kaplan-Meier method and the log-
- 129 rank test. We note that the number of males vs females in the present cohort differs, and thus
- 130 comparing significance by sex is not valid. We also note that our analyses and results are
- 131 hypothesis generating and as such, the findings will require validation in a larger, separate
- 132 dataset. No adjustments for multiple comparisons are made. All statistical analyses were
- 133 performed using R v4.1.0 and p-values < 0.05 were considered significant.

¹³⁵**Results**

136 Baseline and post-treatment clinical characteristics of the r/r B-NHL patient cohort treated with anti-¹³⁷CD19 CAR T-cells are shown in Table 1. The median age was 63 years (range 25-77), and 68.7% of 138 patients in the cohort were male. The median age of males and females was 64.5 years (range 25-77) and ¹³⁹61 years (range 30-74), respectively. The clinical diagnosis was diffuse large B-cell lymphoma (DLBCL) 140 (n = 46, males=35, females=11), transformed follicular lymphoma (n = 12, males=5, females=7), or 141 primary mediastinal B-cell lymphoma ($n = 7$, males=5, females=2), and 40.3% of the patients had 142 received prior autologous stem cell transplantation. Axi-cel was received by 45 patients (males=29, 143 females=16) and tisa-cel was received by 22 patients (males=17, females=5). The median durations for 144 overall survival (OS) and progression-free survival (PFS) were 332 days and 134 days, respectively.

¹⁴⁶**High baseline tumor burden and CRP are associated with poor survival in male patients**

¹⁴⁷We first investigated if there is sex bias in overall and progression-free survival of B-cell NHL patients 148 treated with anti-CD19 CAR T cells. Similar to previous findings in pediatric B-ALL patients treated with 149 CD19-directed CAR T-cells²⁵, male and female r/r B-cell NHL patients did not show a significant 150 difference in the probability of OS (Supplemental Fig. 2A) or PFS (Supplemental Fig. 2B) upon CAR T-¹⁵¹cell therapy. Additionally, the abundance of established baseline risk factors such as tumor burden ¹⁵²(measured as LDH) (Supplemental Fig. 2C) and CRP (Supplemental Fig. 2D) were not different between 153 male and female patients in our cohort. Next, we examined if tumor burden and CRP have different 154 associations with survival when the male and female groups and analyzed separately. A previous study 155 used \geq 250 U/l LDH to stratify high and low tumor burden and identified this marker as the sole predictor 156 of survival²³; therefore, initially we first used the same cut-off in our analysis. Patients who had \geq 250 U/l ¹⁵⁷LDH prior to treatment were at greater risk of poor PFS and OS after axi-cel (n=45) and tisa-cel (n=22) 158 therapy compared to those with <250 U/l LDH (Fig. 1A). Importantly, while male patients with \geq 250 U/l ¹⁵⁹LDH had poorer PFS and OS compared to those with <250 U/l LDH (Fig. 1B), there was no association 160 between LDH concentration and OS or PFS in female patients (Fig. 1C). Next, because \geq 400 U/l LDH

161 was reported to be associated with poor PFS in patients receiving anti-CD19 CAR T-cell therapy²⁴, we 162 also performed association analysis using this cut-off. We found that ≥400 U/l LDH was significantly 163 associated with poor PFS and OS in all patients, and in the male only group, but not in the female only 164 group (Supplemental Fig. 3). Among pre-treatment circulating biomarkers, CRP is an important regulator 165 of inflammation and elevated serum CRP is known to be associated with poor PFS or OS after CAR T-166 cell therapy in multiple myeloma patients²⁶, and DLBCL patients after CAR T-cell therapy²⁷ or 167 chemotherapy²⁸. Hence, we further investigated if CRP levels were associated with differential survival 168 outcomes in separate male and female cohorts. Elevated CRP was significantly associated with poor OS 169 when considering both male and female patients together (Fig. 2A, P=0.0172) or males alone (Fig. 2B, 170 P=0.007), but no association was observed in the female only cohort (Fig. 2C, P=0.7336). On the other 171 hand, elevated CRP was not significantly associated with poor PFS in male and female patients together ¹⁷²(Fig. 2A, P=0.0932) or only males (Fig. 2B, P=0.1028) or only females (Fig. 2C, P=0.5199). It is 173 important to note that while above median CRP abundance showed a trend of association with poor PFS 174 in male and female patients together (Fig. 2A) and only in males (Fig. 2B), this trend was not evident in 175 the female only cohort (Fig. 2C).

¹⁷⁷**High abundance of IL-6, IL-8, IL-27, Eotaxin-1, MIP-1**β **and MCP-1 associated with poor survival** ¹⁷⁸**in male patients**

179 Because CRP is an important inflammatory biomarker, we examined if the pre-treatment levels of other 180 serum cytokines/chemokines that mediate inflammation during CAR T-cell therapy were different 181 between male and female patients. For this study, we chose 29 cytokines/chemokines (IL-1RA, IL-3, IL-182 4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-15, IL-18, IL-21, IL-27, IFNα2, IFN-γ, TNF-α, Eotaxin-1, MIP-183 1α, MIP-1β, MCP-1, Flt3L, Fractalkine, G-CSF, GM-CSF, IP-10, MDC, RANTES, sCD40L and VEGF-¹⁸⁴A) that are of myeloid and lymphoid origin and play essential roles in innate and/or adaptive immunity. 185 With the exception of IL-3, the relative abundance of baseline circulating cytokines and chemokines was

186 not significantly different between male and female patients (Fig. 3). We reasoned that despite no 187 observable differences in abundance, these cytokine/chemokines may have different interactions with the 188 male vs. female immune environment and could therefore be associated differentially with survival in 189 each sex. To investigate this, the association of cytokine abundance with survival was analyzed separately 190 for only male, only female or both sexes together. The relative abundance of specific 191 cytokines/chemokines within each cohort was classified as either below or above median, and median 192 abundance is indicated for each cohort and cytokine in PFS and OS association analysis. When both sexes 193 were analyzed together, poorer PFS was found to be associated with higher abundance of MIP-1β and 194 Eotaxin-1 (P<0.05), and IL-8 (P=0.074) (Fig. 4). When associations of cytokine abundance with PFS 195 were analyzed separately in male only and female only patients, higher abundance of IL-8, Eotaxin-1, 196 MIP-1β (P<0.05), IL-6 (P=0.075), and MCP-1 (P=0.086) were associated with poor PFS in male patients ¹⁹⁷(Fig. 4). The abundance of these cytokines had no observable associations with PFS in the female only 198 cohort but elevated IL-27 was significantly associated with better PFS in females (Fig. 4). Higher relative 199 abundance of IL-6, IL-8, IL-27, Eotaxin-1, MCP-1, and TNF-α was also significantly associated (P<0.05) 200 with poorer OS when considering the male only cohort; but no observable difference in OS was found in 201 the female only cohort for these cytokines. (Fig. 5). Interestingly, IFN α 2 was the only cytokine whose 202 higher relative abundance was associated with poor OS ($P=0.07$) within the female only cohort (Fig. 5). 203 Higher abundance of IL-6 was associated $(P<0.05)$ with poor OS when male and female sexes were ²⁰⁴analyzed together or in the male only cohort, but no association was observed in the female only cohort ²⁰⁵(Fig. 5). While IL-7 is an important T-cell promoting cytokine, its pre-treatment abundance was not 206 associated with PFS (Fig. 4) or OS (Fig. 5). Additionally, the relative abundance of IL-1RA, IL-3, IL-4, ²⁰⁷IL-9, IL-10, IL-15, IL-18, IL-21, Flt3L, Fractalkine, G-CSF, GM-CSF, IP-10, MDC, RANTES, sCD40L, 208 and VEGF-A showed no association with PFS (Supplemental Fig. 4) or OS (Supplemental Fig. 5) in male 209 or female patients. These data indicate that despite similar overall abundance of the analyzed cytokines in 210 male and female r/r B-NHL patients, the association of their individual relative abundance with survival 211 after anti-CD19 CAR T-cell therapy varies in a sex-biased manner.

212

- ²¹³Taken together, our results demonstrate that higher tumor burden, CRP, IL-6, IL-27, TNF-α, IL-8,
- 214 Eotaxin-1, MIP-1β and MCP-1 represent a novel signature of poor survival in male, but not female B-
- 215 NHL patients treated with anti-CD19 CAR T-cells.

²¹⁷**Discussion**

²¹⁸A variety of pre-treatment biomarkers of clinical outcomes have been reported in LBCL patients 219 undergoing anti-CD19 CAR T-cell therapy^{29,30}. However, the impact of sex on the association between 220 pre-treatment tumor and immune environment and survival after CAR T-cell therapy has not been 221 comprehensively explored. Here, we demonstrate that higher baseline tumor burden and greater relative 222 abundance of a pre-treatment inflammatory signature consisting of IL-8, IL-6, TNF-α, Eotaxin-1, MIP-²²³1β, MCP-1 and CRP confers risk of poor survival in male patients treated with anti-CD19 CAR T-cells. ²²⁴On the other hand, female patients undergoing CAR T-cell therapy do not show an association between 225 the relative abundance of these pre-treatment biomarkers and survival. Our findings are consistent with 226 the tenet that the immune system has different interactions in the male and female sex and that this plays a 227 role in establishing sex differences in response to immunotherapy.

228

²²⁹A pan-cancer analysis demonstrated sex as a significant factor influencing cancer-specific survival and 230 females have better prognosis than male patients in most cancers³¹. In B-cell lymphoma patients, the male 231 sex is an adverse prognostic factor when treated with immunochemotherapy but not when treated with 232 chemotherapy³². Our finding that higher baseline tumor burden predisposes only male patients to a poor 233 survival outcome indicates sex bias in outcomes of CAR T-cell therapy. Specific components of tumors 234 in males may play a role in this predisposition, such as high circulating cytokine levels and monocytic-235 myeloid-derived suppressor cells (mMDSCs), both of which are associated with resistance to CAR T-cell 236 therapy³⁰. Interestingly, males have higher levels of mMDSCs in general³³ and this is thought to be one of 237 the sex-specific mechanisms that prevents autoimmune diseases and underlies poorer response to 238 infections³⁴. Along these lines, CRP, another known biomarker of poor prognosis in r/r DLBCL after 239 CAR T-cell therapy²⁷, was reported to support the expansion of MDSCs and suppression of T cell 240. proliferation³⁵. It is conceivable that male patients with larger tumor burden have higher levels of

241 mMDSCs which interfere with CAR T-cell activity. Therefore, the association of higher pre-treatment ²⁴²CRP and tumor burden with poor survival suggests the existence of an unfavorable immune environment 243 in male r/r B-NHL patients that may limit optimal CAR T-cell activity.

244

245 Inflammatory cytokines and chemokines are important for the activation of T cell-mediated immune 246 reactions and recruitment of myeloid cells, and together these soluble factors facilitate CAR T-cell 247 activity³⁶⁻³⁸. Remarkably, we did not observe a significant difference in the serum abundance of 248 cytokines/chemokines between male and female r/r B-NHL patients treated with anti-CD19 CAR T-cells, 249 with the exception of IL-3. Yet, in male patients, higher pre-treatment abundance of IL-6, IL-8, IL-27, ²⁵⁰TNF-α, Eotaxin-1 and MIP-1β confers risk of poor survival outcomes. As these associations are not 251 observed in female patients, our findings indicate that the manner in which these cytokines interact with 252 the male environment may be different from that in the female environment, and likely confers poor 253 survival probability in the former. Interestingly, IL-6, TNF- α , IL-8, MIP-1 β and MCP-1 are known to be 254 associated with tumor burden and tumor growth in various cancers³⁹⁻⁴². High tumor burden is associated 255 with the IL-6 signaling pathway⁴³ and with elevated levels of TNF- α^{44} and CRP⁴⁵ in aggressive cancers. 256 Additionally, inflammatory stimuli such as IL-6 can indirectly induce the expression of chemokine 257 mediators such as MCP-1⁴⁶⁻⁴⁸ which recruit MDSCs and support tumor growth⁴⁹. Eotaxin-1 is a CC 258 subfamily chemokine similar to MCP-1⁴⁷ and is reported to inhibit antitumor immunity^{50,51}. Therefore, the 259 association of higher relative abundance of IL-8, IL-6, TNF-α, Eotaxin-1, MIP-1β and MCP-1with poor 260 survival probability in the male patients suggests a unique interaction network between the tumor and 261 circulating environments that predisposes male patients to poorer survival outcomes after anti-CD19 CAR 262 T-cell therapy. Indeed, some of these interactions may be mediated by sex hormones⁵², social 263 behaviors^{53,54}, chromosomal genetics⁵⁵, and sex chromosome-encoded genetic environment in the male 264 sex^{56} .

266 While a majority of associations described here impact survival outcomes in male r/r B-NHL patients, 267 there were notable associations between abundance of two cytokines with survival in female r/r B-NHL 268 patients – IL-27 and IFN α 2. Female patients with higher relative abundance of IL-27 showed significant 269 association with better PFS, and those with higher abundance of IFN α 2 showed poorer OS. IL-27 is a 270 pleiotropic cytokine with both pro- and anti-inflammatory activities and IL-27 expressing T cells 271 demonstrate sustained anti-tumor immunity and cytotoxicity⁵⁷. Interestingly, our data reveal context-²⁷²specific associations of this cytokine – in male patients elevated abundance increases risk of poor overall 273 survival, yet in female patients, higher abundance of IL-27 predicts better progression-free survival. The 274 molecular basis of this difference is unclear and deserves future investigation. Type I IFNs, specifically 275 IFN α , are a primary source of pathogenesis in autoimmune diseases such as systemic lupus 276 erythematosus that exhibit a strong female sex bias⁵⁸. Therefore, female r/r B-NHL patients who have ²⁷⁷higher abundance of IFNα2 may experience similar inflammatory pathologies that affect their overall 278 survival after CAR T-cell therapy. The mechanistic basis of the unique associations between the 279 abundance of IL-27 and IFN α 2 and survival in only the female patients in our cohort is currently unclear 280 and will need to be further investigated.

282 A few limitations should be considered when inferring the findings of our study. First, the relatively small 283 sample size currently limits the generalizability our findings to a larger population. Further, other factors, 284 such as ethnicity, race, type of lymphoma, type of CAR T-cell therapy and the use of bridging therapy 285 may influence the outcome of CAR T-cell therapy response in a sexually dimorphic manner. We were 286 unable to investigate these factors, either due to lack of available data or small cohort size. Despite these 287 limitations, our pilot study suggests that the observed differences in clinical survival outcome in male and ²⁸⁸female patients are primarily driven by different biological interactions of cytokines and tumor

289 microenvironment in each sex. Further research is needed to validate this hypothesis and explore the 290 underlying mechanisms.

291

²⁹⁸**Acknowledgments**

³⁰³**Authorship Contributions**

³⁰⁴M.S.P. and A.J. collected and processed the blood samples; M.S.P. and A.M. collected clinical data; ³⁰⁵M.S.P., P.B., S. P., B.T.H., and N.G. analyzed the data; M.S.P., S.P., B.T.H., and N.G. wrote the 306 manuscript; B.T.H. and N.G. provided funding support; and N.G. conceptualized and supervised the 307 study.

³⁰⁹**Disclosure of Potential Conflicts of Interest**

310 B.T.H. has received research funding from Takeda; Consultancy, Honoraria, Research Funding from ³¹¹Genentech, Karyopharm, Celgene, Abbvie, Pharmacyclics, Beigene, AstraZenica, Kite, a Gilead 312 Company, BMS; Consultancy, Honoraria from Novartis.

313

³¹⁴**Data sharing statement**

315 For original data, please contact the corresponding author (guptan@ccf.org).

References

- 2. Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in 321 Refractory Large B-Cell Lymphoma. *N Engl J Med.* 2017;377(26):2531-2544.
- 3. Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in Adult Relapsed or Refractory 323 Diffuse Large B-Cell Lymphoma. *N Engl J Med.* 2019;380(1):45-56.
- 4. Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma:
- results from the international SCHOLAR-1 study. *Blood*. 2017;130(16):1800-1808.
- 5. Locke FL, Siddiqi T, Jacobson CA, et al. Real-world and clinical trial outcomes in large B-cell
- lymphoma with axicabtagene ciloleucel across race and ethnicity. *Blood*. 2024;143(26):2722-2734.
- 6. Mersha TB, Abebe T. Self-reported race/ethnicity in the age of genomic research: its potential 329 impact on understanding health disparities. *Hum Genomics*. 2015;9(1):1.
- 7. Turner BE, Steinberg JR, Weeks BT, Rodriguez F, Cullen MR. Race/ethnicity reporting and representation in US clinical trials: A cohort study. *The Lancet Regional Health – Americas*. 2022;11.
- 8. Klein SL. The effects of hormones on sex differences in infection: from genes to behavior. *Neurosci Biobehav Rev*. 2000;24(6):627-638.
- 9. Afshan G, Afzal N, Qureshi S. CD4+CD25(hi) regulatory T cells in healthy males and females 335 mediate gender difference in the prevalence of autoimmune diseases. *Clin Lab*. 2012;58(5-6):567-571.
- 10. Billi AC, Kahlenberg JM, Gudjonsson JE. Sex bias in autoimmunity. *Curr Opin Rheumatol*. 2019;31(1):53-61.

11. Rubtsova K, Marrack P, Rubtsov AV. Sexual dimorphism in autoimmunity. *J Clin Invest*. 2015;125(6):2187-2193.

12. Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. *Science*. 2018;359(6382):1350-1355.

13. Wang PF, Song HF, Zhang Q, Yan CX. Pan-cancer immunogenomic analyses reveal sex 343 disparity in the efficacy of cancer immunotherapy. *Eur J Cancer*. 2020;126:136-138.

14. Saad M, Tan AC, Naqa IE, et al. 88 Evidence of enhanced immune activation within the tumor microenvironment and the circulation of female patients with high-risk melanoma compared to males. *^J Immunother Cancer*. 2021;9(Suppl 2):A96-A96.

15. Lefèvre N, Corazza F, Valsamis J, et al. The Number of X Chromosomes Influences Inflammatory Cytokine Production Following Toll-Like Receptor Stimulation. *Front Immunol*. 2019;10:1052.

16. Berghella AM, Contasta I, Lattanzio R, et al. The Role of Gender-specific Cytokine Pathways as 351 Drug Targets and Gender- specific Biomarkers in Personalized Cancer Therapy. *Curr Drug Targets*. 2017;18(4):485-495.

17. Santoni M, Rizzo A, Mollica V, et al. The impact of gender on The efficacy of immune 354 checkpoint inhibitors in cancer patients: The MOUSEION-01 study. *Crit Rev Oncol Hematol*. 355 2022;170:103596.

18. Grassadonia A, Sperduti I, Vici P, et al. Effect of Gender on the Outcome of Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer: A Systematic Review and Meta-Analysis of Phase 358 III Randomized Clinical Trials. *J Clin Med.* 2018;7(12):542.

³⁵⁹19. Burkhardt B, Zimmermann M, Oschlies I, et al. The impact of age and gender on biology, clinical ³⁶⁰features and treatment outcome of non-Hodgkin lymphoma in childhood and adolescence. *Br J Haematol*. ³⁶¹2005;131(1):39-49.

362 20. Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence ³⁶³patterns by WHO subtype in the United States, 1992-2001. *Blood*. 2006;107(1):265-276.

³⁶⁴21. Jalota A, Hershberger CE, Patel MS, et al. Host metabolome predicts the severity and onset of ³⁶⁵acute toxicities induced by CAR T-cell therapy. *Blood Advances*. 2023;7(17):4690-4700.

³⁶⁶22. Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and ³⁶⁷response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. *J Clin Oncol*. 368 2014;32(27):3059-3068.

³⁶⁹23. Suguro M, Kanda Y, Yamamoto R, et al. High serum lactate dehydrogenase level predicts short 370 survival after vincristine-doxorubicin-dexamethasone (VAD) salvage for refractory multiple myeloma. ³⁷¹*Am J Hematol*. 2000;65(2):132-135.

³⁷²24. Karschnia P, Jordan JT, Forst DA, et al. Clinical presentation, management, and biomarkers of 373 neurotoxicity after adoptive immunotherapy with CAR T cells. *Blood*. 2019;133(20):2212-2221.

³⁷⁴25. Faruqi AJ, Ligon JA, Borgman P, et al. The impact of race, ethnicity, and obesity on CAR T-cell 375 therapy outcomes. *Blood Adv.* 2022;6(23):6040-6050.

³⁷⁶26. Liu Y, Jie X, Nian L, et al. A combination of pre-infusion serum ferritin, CRP and IL-6 predicts 377 outcome in relapsed/refractory multiple myeloma patients treated with CAR-T cells. *Frontiers in* ³⁷⁸*Immunology*. 2023;14.

³⁷⁹27. Vercellino L, Di Blasi R, Kanoun S, et al. Predictive factors of early progression after CAR T-cell 380 therapy in relapsed/refractory diffuse large B-cell lymphoma. *Blood Adv.* 2020;4(22):5607-5615.

28. Troppan KT, Schlick K, Deutsch A, et al. C-reactive protein level is a prognostic indicator for 382 survival and improves the predictive ability of the R-IPI score in diffuse large B-cell lymphoma patients. *British Journal of Cancer*. 2014;111(1):55-60.

29. Faramand R, Jain M, Staedtke V, et al. Tumor Microenvironment Composition and Severe Cytokine Release Syndrome (CRS) Influence Toxicity in Patients with Large B-Cell Lymphoma Treated

386 with Axicabtagene Ciloleucel. *Clin Cancer Res.* 2020;26(18):4823-4831.

387 30. Jain MD, Zhao H, Wang X, et al. Tumor interferon signaling and suppressive myeloid cells are 388 associated with CAR T-cell failure in large B-cell lymphoma. *Blood*. 2021;137(19):2621-2633.

31. He Y, Su Y, Zeng J, et al. Cancer-specific survival after diagnosis in men versus women: A pan-

390 cancer analysis. *MedComm (2020)*. 2022;3(3):e145.

32. Riihijärvi S, Taskinen M, Jerkeman M, Leppä S. Male gender is an adverse prognostic factor in

B-cell lymphoma patients treated with immunochemotherapy. *Eur J Haematol*. 2011;86(2):124-128.

33. Bayik D, Zhou Y, Park C, et al. Myeloid-Derived Suppressor Cell Subsets Drive Glioblastoma Growth in a Sex-Specific Manner. *Cancer Discov*. 2020;10(8):1210-1225.

34. Kiaee F, Jamaati H, Shahi H, et al. Immunophenotype and function of circulating myeloid derived suppressor cells in COVID-19 patients. *Scientific Reports*. 2022;12(1):22570.

35. Jimenez RV, Kuznetsova V, Connelly AN, Hel Z, Szalai AJ. C-Reactive Protein Promotes the Expansion of Myeloid Derived Cells With Suppressor Functions. *Front Immunol*. 2019;10:2183.

399 36. Umansky V, Blattner C, Gebhardt C, Utikal J. The Role of Myeloid-Derived Suppressor Cells

(MDSC) in Cancer Progression. *Vaccines (Basel)*. 2016;4(4):36.

37. Schlecker E, Stojanovic A, Eisen C, et al. Tumor-infiltrating monocytic myeloid-derived suppressor cells mediate CCR5-dependent recruitment of regulatory T cells favoring tumor growth. *^J Immunol*. 2012;189(12):5602-5611.

38. Salomon BL, Leclerc M, Tosello J, Ronin E, Piaggio E, Cohen JL. Tumor Necrosis Factor α and Regulatory T Cells in Oncoimmunology. *Front Immunol*. 2018;9:444.

39. Sanmamed MF, Carranza-Rua O, Alfaro C, et al. Serum interleukin-8 reflects tumor burden and 407 treatment response across malignancies of multiple tissue origins. *Clin Cancer Res.* 2014;20(22):5697-5707.

40. Gazzaniga S, Bravo AI, Guglielmotti A, et al. Targeting Tumor-Associated Macrophages and Inhibition of MCP-1 Reduce Angiogenesis and Tumor Growth in a Human Melanoma Xenograft. *Journal of Investigative Dermatology*. 2007;127(8):2031-2041.

41. Mazur G, Wróbel T, Butrym A, Kapelko-Słowik K, Poreba R, Kuliczkowski K. Increased monocyte chemoattractant protein 1 (MCP-1/CCL-2) serum level in acute myeloid leukemia. *Neoplasma*. 2007;54(4):285-289.

415 42. Zhang L, Zhang M, Wang L, et al. Identification of CCL4 as an Immune-Related Prognostic 416 Biomarker Associated With Tumor Proliferation and the Tumor Microenvironment in Clear Cell Renal Cell Carcinoma. *Front Oncol*. 2021;11:694664.

418 43. Hashwah H, Bertram K, Stirm K, et al. The IL-6 signaling complex is a critical driver, negative prognostic factor, and therapeutic target in diffuse large B-cell lymphoma. *EMBO Molecular Medicine*. 420 2019;11(10):e10576.

44. Mozas P, Rivas-Delgado A, Rivero A, et al. High serum levels of IL-2R, IL-6, and TNF-α are 422 associated with higher tumor burden and poorer outcome of follicular lymphoma patients in the rituximab era. *Leukemia Research*. 2020;94:106371.

- 45. Koukourakis MI, Kambouromiti G, Pitsiava D, Tsousou P, Tsiarkatsi M, Kartalis G. Serum C-
- 425 reactive Protein (CRP) Levels in Cancer Patients are Linked with Tumor Burden and are Reduced by
- Anti-hypertensive Medication. *Inflammation*. 2009;32(3):169-175.
- 427 46. Choi S, You S, Kim D, et al. Transcription factor NFAT5 promotes macrophage survival in rheumatoid arthritis. *J Clin Invest*. 2017;127(3):954-969.
- 429 47. Van Coillie E, Van Damme J, Opdenakker G. The MCP/eotaxin subfamily of CC chemokines. *Cytokine Growth Factor Rev*. 1999;10(1):61-86.
- 431 48. Yoshimura T. The chemokine MCP-1 (CCL2) in the host interaction with cancer: a foe or ally? *Cell Mol Immunol*. 2018;15(4):335-345.
- 433 49. Mittal P, Wang L, Akimova T, et al. The CCR2/MCP-1 Chemokine Pathway and Lung Adenocarcinoma. *Cancers (Basel)*. 2020;12(12):3723.
- 50. Wang R, Huang K. CCL11 increases the proportion of CD4+CD25+Foxp3+ Treg cells and the production of IL2 and TGFβ by CD4+ T cells via the STAT5 signaling pathway. *Mol Med Rep*. 2020;21(6):2522-2532.
- 51. Yang J, Hawkins OE, Barham W, et al. Myeloid IKKβ Promotes Antitumor Immunity by Modulating CCL11 and the Innate Immune Response. *Cancer Research*. 2014;74(24):7274-7284.
- 52. Conforti F, Pala L, Goldhirsch A. Different effectiveness of anticancer immunotherapy in men and women relies on sex-dimorphism of the immune system. *Oncotarget*. 2018;9(58):31167-31168.
- 53. Kim SY, Lee S, Lee E, et al. Sex-biased differences in the correlation between epithelial-to-mesenchymal transition-associated genes in cancer cell lines. *Oncol Lett*. 2019;18(6):6852-6868.
- 54. Zhu Y, Shao X, Wang X, Liu L, Liang H. Sex disparities in cancer. *Cancer Lett*. 2019;466:35-38.

⁴⁴⁹56. Klein SL, Flanagan KL. Sex differences in immune responses. *Nature Reviews Immunology*. ⁴⁵⁰2016;16(10):626-638.

451 57. Afsahi A, Burchett R, Baker CL, Moore AE, Bramson JL. Constitutive expression of interleukin-

452 27 diminishes proinflammatory cytokine production without impairing effector function of engineered T

⁴⁵³cells. *Cytotherapy*. 2023;25(9):913-919.

⁴⁵⁴58. Postal M, Vivaldo JF, Fernandez-Ruiz R, Paredes JL, Appenzeller S, Niewold TB. Type I ⁴⁵⁵interferon in the pathogenesis of systemic lupus erythematosus. *Curr Opin Immunol*. 2020;67:87-94.

⁴⁵⁷**Table 1: Baseline and post-treatment clinical characteristics**

458

^{459 &}lt;sup>a</sup>CR: Complete response, PR: Partial response, OR: Overall response (CR+PR), NR: No response

⁴⁶⁰(Progressive disease, Stable disease, Death); LDH: Lactate Dehydrogenase

⁴⁶²**Figure Legends**

463

⁴⁶⁴**Figure 1. Male patients with higher pre-treatment tumor burden show poorer survival after treated**

477

⁴⁷⁸**Figure 4. Male patients with elevated pre-treatment abundance of IL-8, Eotaxin-1 and MIP-1**^β ⁴⁷⁹**show poorer PFS upon treatment with anti-CD19 CAR T-cells.** Association between relative 480 abundance of the indicated cytokines and PFS in both male and female, or only male or only female 481 LBCL patients. P<0.05; Males, n=42; Females, n=20; Yes, n=42; Kym, n=20.

- ⁴⁸³**Figure 5. Male patients with elevated pre-treatment abundance of IL-6, IL-8, IL-27, Eotaxin-1,**
- ⁴⁸⁴**MCP-1 and TNF-**α **show poorer OS upon treatment with anti-CD19 CAR T-cells.** Association
- 485 between relative abundance of the indicated cytokines and OS in both male and female, or only male or
- 486 only female LBCL patients. P<0.05; Males, n=42; Females, n=20; Yes, n=42; Kym, n=20.

Figure 1

Figure 2

